Your browser doesn't support javascript.
loading
Plasma circulating cell-free mitochondrial DNA in depressive disorders.
Fernström, Johan; Ohlsson, Lars; Asp, Marie; Lavant, Eva; Holck, Amanda; Grudet, Cécile; Westrin, Åsa; Lindqvist, Daniel.
Affiliation
  • Fernström J; Department of Clinical Sciences Lund, Psychiatry, Faculty of Medicine, Lund University, Lund, Sweden.
  • Ohlsson L; Office for Psychiatry and Habilitation, Psychiatric Clinic Lund, Region Skåne, Sweden.
  • Asp M; Department of Biomedical Science, Malmö University, Health and Society, Malmö, Sweden.
  • Lavant E; Department of Clinical Sciences Lund, Psychiatry, Faculty of Medicine, Lund University, Lund, Sweden.
  • Holck A; Office for Psychiatry and Habilitation, Psychiatric Clinic Lund, Region Skåne, Sweden.
  • Grudet C; Department of Biomedical Science, Malmö University, Health and Society, Malmö, Sweden.
  • Westrin Å; Department of Clinical Sciences Lund, Psychiatry, Faculty of Medicine, Lund University, Lund, Sweden.
  • Lindqvist D; Office for Psychiatry and Habilitation, Psychiatric Clinic Lund, Region Skåne, Sweden.
PLoS One ; 16(11): e0259591, 2021.
Article in En | MEDLINE | ID: mdl-34735532
ABSTRACT

BACKGROUND:

Plasma circulating cell-free mitochondrial DNA (ccf-mtDNA) is an immunogenic molecule and a novel biomarker of psychiatric disorders. Some previous studies reported increased levels of ccf-mtDNA in unmedicated depression and recent suicide attempters, while other studies found unchanged or decreased ccf-mtDNA levels in depression. Inconsistent findings across studies may be explained by small sample sizes and between-study variations in somatic and psychiatric co-morbidity or medication status.

METHODS:

We measured plasma ccf-mtDNA in a cohort of 281 patients with depressive disorders and 49 healthy controls. Ninety-three percent of all patients were treated with one or several psychotropic medications. Thirty-six percent had a personality disorder, 13% bipolar disorder. All analyses involving ccf-mtDNA were a priori adjusted for age and sex.

RESULTS:

Mean levels in ccf-mtDNA were significantly different between patients with a current depressive episode (n = 236), remitted depressive episode (n = 45) and healthy controls (n = 49) (f = 8.3, p<0.001). Post-hoc tests revealed that both patients with current (p<0.001) and remitted (p = 0.002) depression had lower ccf-mtDNA compared to controls. Within the depressed group there was a positive correlation between ccf-mtDNA and "inflammatory depression symptoms" (r = 0.15, p = 0.02). We also found that treatment with mood stabilizers lamotrigine, valproic acid or lithium was associated with lower ccf-mtDNA (f = 8.1, p = 0.005).

DISCUSSION:

Decreased plasma ccf-mtDNA in difficult-to-treat depression may be partly explained by concurrent psychotropic medications and co-morbidity. Our findings suggest that ccf-mtDNA may be differentially regulated in different subtypes of depression, and this hypothesis should be pursued in future studies.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: DNA, Mitochondrial / Biomarkers / Cell-Free Nucleic Acids / Mental Disorders Type of study: Diagnostic_studies Limits: Humans Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2021 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: DNA, Mitochondrial / Biomarkers / Cell-Free Nucleic Acids / Mental Disorders Type of study: Diagnostic_studies Limits: Humans Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2021 Document type: Article Affiliation country: